drugset / Trial / NCT03887325

The Effects of Maxipost (BMS 204352) on Cerebral Hemodynamic and Headache in Healthy Volunteers and Migraine Patients

NCT03887325 ↗

Completed 43 enrolled Danish Headache Center
RandomizedCrossoverQuadruple-blindOther

Summary

It is not previously investigated whether, there is a correlation between potassium channels and migraine, so it is unclear whether, this signaling pathway through potassium channels has an impact on migraine pathophysiology. Maxipost (BMS 204352) is a vasoactive molecule that causes vasodilation via the big calcium dependent potassium (BKCa) channel signaling pathway. Maxipost decreases the blood pressure and maxipost infusion causes headache in healthy volunteers. A possible coherence between maxipost and headache/migraine in healthy volunteers and migraine patients is yet to be investigated. The present study aims to clarify a possible coherence between maxipost and headache/migraine and it will help to shed light on the importance of potassium channels in migraine. In general, the study will contribute to a greater understanding of migraine pathogenesis and possibly lead to development of specific migraine treatment.

Timeline

Start
2019-04-01
Primary completion
2020-02-29
Completion
2020-02-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator FLINDOKALNER Small molecule 0.05 mg Intravenous

Indications